Theme based on nuclear medicine :
innovative radionuclides for diagnosis and treatment in oncology
By producing innovative radionuclides covering a large radioactivity emission and half-live spectrum, and by understanding physiopathological mechanisms such as hypoxia, expression of antigens and radiobiological and immune responses, this area aims :
- to conceive new biological vectors
- to transfer to clinic new radiopharmaceutical products, by proving their relevance both in functional and phenotypic tumour imaging and in radioimmunotherapy (RIT).
Thus, this area performs translational research in the field of molecular imagining (PET, quantitative full body imaging, dosimetry) and targeted molecular radiotherapy (RIT, alpha-immunotherapy), based on fundamental research in chemistry and radiochemistry, radiobiology, immunology and oncology in the DHU’s tumours of interest:
- hemopathies (multiple myeloma (MM), lymphoma and acute leukaemia)
- digestive tumours (colo-rectal carcinomas and neuro-endocrine tumours)
- urological tumours
This area includes 9 transversal aims organised around 3 main themes :
Theme 1. Innovative radionuclides and radiopharmaceuticals
Aim 1.1. Production of innovative radionuclides and new radiopharmaceuticals.
Production of new products according to good manufacturing practice to accelerate the development of innovative PET molecular imaging strategies (68Ga, 124I, 64Cu, 44Sc) and radionuclide molecular therapies (211At, 67Cu, 47Sc)
Aim 1.2. Radiolabeling of vectors with novel radionuclides.
Development, validation and evaluation of new radiopharmacy protocols for transfer to clinic
Preparation of reglementary files.
Theme 2. Radioimmunotherapy
Aim 2.1.Assessment of immune response to RIT (MM).
Study of radiobiological and immunological response mechanisms to RIT and alpha-immunotherapy .
- Aim 2.2. . Preclinical validation of innovative radiopharmaceuticals for RIT and alpha-immunotherapy (MM, lymphoma, colorectal, prostate and breast carcinoma).
Preclinical validation of RIT beta and alpha-RIT in relevant small animal models (murine xenotransplant and syngenic models) or large animal models (spontaneous tumours in dogs or cats)
Development of nano-vectors.
- Aim 2.3. Transfer to clinic of innovative RIT approaches (MM, lymphoma, colorectal and prostate carcinoma, acute lymphoblastic leukaemia).
Clinical validation of new RIT approaches : CD22 targeting, pre-targeting, anti-PSMA labeled with 177Lu and 211At
Aim 2.4. Dosimetry.
Dose-effect relationship analysis in the context of RIT and alpha-immunotherapy.
Theme 3. Functional and tumour phenotype imaging
Aim 3.1. Quantitative imaging of innovative radionuclides.
Development of the quantification of innovative radionuclides produced by ARRONAX.
Development of a Compton-3-photon PET camera for scandium 44 imaging.
Development of original pharmacokinetic (PK) methods in the context of immuno-targeting.
Aim 3.2. Preclinical validation of innovative radiopharmaceuticals for functional and immuno-PET (MM, breast, medullary thyroid, colorectal carcinoma).
Preclinical validation of new radiopharmaceuticals for immuno-PET and tumour hypoxia imaging in relevant animal models on the ONIRIS and the CRCINA animal imaging platforms.
Aim 3.3. Transfer to clinic of innovative radiopharmaceuticals for PET imaging (MM, breast carcinoma, medullary thyroid, colorectal, prostate, endocrine tumours)
Validation en clinique l’immuno-TEP et l’imagerie phénotypique des tumeurs solides (préciblage, peptide)
Clinical validation of immuno-PET and phenotype imaging of solid tumours (pretargeting, peptide)
Programme partners :
- The Arronax cyclotron
- The LabEX IRON
- The theme Vectorisation and radiotherapy area by the Cancéropôle Grand Ouest
- NucSan project financed by the Pays De Loire region
- Subatech chemistry and radiochemistry teams
- The CRCINA Nuclear Oncology research team
- The CHU department of Nuclear medecine
- Institut de Cancérologie de l’Ouest (ICO)
- Oniris CRIP.